Effect of Rosiglitazone
Information source: University Hospital, Montpellier
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: rosiglitazone (Drug)
Phase: N/A
Status: Completed
Sponsored by: University Hospital, Montpellier Official(s) and/or principal investigator(s):
PIERRE PETIT, MD-PhD, Principal Investigator, Affiliation: Centre d'Investigation Clinique
Summary
To evaluate :
- acute effects of a single dose of 8 mg rosiglitazone (therapeutic dose)
- on insulin secretion and
- insulin sensitivity in 12 healthy male subjects.
Clinical Details
Official title: Assessment of the Effect of Rosiglitazone on Insulin Secretion in Healthy Volunteers
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Pharmacodynamics Study
Primary outcome: insulin response and insulin sensitivity assessed by 2-hours 10 mmol/l hyperglycemic clamp, started 45 min after treatment intake
Secondary outcome: insulin clearancebasal glycemia and insulinemia tolerance
Eligibility
Minimum age: 18 Years.
Maximum age: 35 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- BMI between 18. 0 and 24. 0
Exclusion Criteria:
-
Locations and Contacts
Centre d'Investigation Clinique, Montpellier 34295, cedex 5, France
Additional Information
Starting date: June 2004
Ending date: November 2004
Last updated: October 5, 2006
|
